Biopharma Business

Tag "metastatic breast cancer"

FDA accepts regulatory submission for Lynparza in metastatic breast cancer

    FDA accepts regulatory submission for Lynparza in metastatic breast cancer

Lynparza has the potential to offer a new treatment option for patients with metastatic breast cancer. AstraZeneca and Merck & Co., have announced that the US Food and Drug Administration

Read Full Article

Upcoming Events

[eventlist]

The Magazine

New Subscriber

Subscribe Here



Advertisements